

1 Article

# 2 Biological Effects of Amelogenin Exon 5 Encoded 3 Peptide from Enamel Matrix Derivative in Human 4 Dental Pulp Cells

5 Hirohito Kato <sup>1</sup>, Yoichiro Taguchi <sup>1\*</sup>, Kazuya Tominaga <sup>2</sup>, Masahiro Noguchi <sup>1</sup>, Kazutaka Imai <sup>1</sup>,  
6 Ruan Yaru <sup>1</sup>, Saitatsu Takahashi <sup>1</sup>, Daisuke Kimura <sup>1</sup>, Muneyasu Shida <sup>3</sup>, Reiko Taguchi <sup>3</sup>, Hiroshi  
7 Maeda <sup>3</sup>, Akio Tanaka <sup>2</sup>, and Makoto Umeda <sup>1</sup>

8 <sup>1</sup> Department of Periodontology, Osaka Dental University, Osaka, Japan; E-Mails: kato-h@cc.osaka-  
9 dent.ac.jp (H.K.); taguchi@cc.osaka-dent.ac.jp (Y.T.); noguchi@cc.osaka-dent.ac.jp (M.N.); imai-k@cc.osaka-  
10 dent.ac.jp (K.I.); ruan-y@cc.osaka-dent.ac.jp (Y.R.); takahashi-s@cc.osaka-dent.ac.jp (S.T.) kimura-  
11 d@cc.osaka-dent.ac.jp (D.K.); umeda-m@cc.osaka-dent.ac.jp (M.U.)

12 <sup>2</sup> 2Department of Oral Pathology, Osaka Dental University, Osaka, Japan; E-Mails: tominaga@cc.osaka-  
13 dent.ac.jp (K.T.); tanaka@cc.osaka-dent.ac.jp (A.T.)

14 <sup>3</sup> Department of Endodontics, Osaka Dental University, Osaka, Japan; E-Mails: shida@cc.osaka-dent.ac.jp  
15 (M.S.); taguchi-r@cc.osaka-dent.ac.jp (R.T.); maeda-h@cc.osaka-dent.ac.jp (H.M.)

16 \* Correspondence: taguchi@cc.osaka-dent.ac.jp; Tel.: +81-72-864-3084

17 **Abstract:** Enamel matrix derivative (EMD) is used for periodontal tissue regeneration therapy, and  
18 can induce mineralization in dental pulp cells (DPCs). We designed a synthetic peptide (SP) derived  
19 from the response of cells to EMD, and investigated the effect of the SP on potentiating osteogenesis  
20 in DPCs, which have a critical role of dental pulp homeostasis. DPCs were treated with 0, 10, 100,  
21 or 1000 ng/mL SP to determine its effect on cell proliferation, cell migration, cell differentiation, and  
22 mineralization. We then examined the molecular effects of the SP, focusing on changes in the  
23 mitogen-activated protein kinases (MAPK) signaling pathway in these cells. The SP significantly  
24 promoted DPC proliferation and migration. Cultures treated with the SP also showed an enhanced  
25 expression of markers of osteogenic differentiation and mineralization. The SP also induced the  
26 activation of MAPK signaling pathway components. These results suggest that our SP could  
27 promote the dental pulp tissue repair by hard tissue formation and the mineralization through  
28 activating MAPK signaling pathway. This study provides the first evidence that SP might be a new  
29 material for dental pulp tissue treatment.

30 **Keywords:** Emdogain; amelogenin; dental pulp cells; cell differentiation; cell migration;  
31 mineralization

## 32 1. Introduction

33 Dental caries, tooth fracture, and other types of dental trauma require measures that can repair  
34 the tooth and dental pulp. Direct pulp capping and partial pulpotomy treatments are used to seal the  
35 exposed dental pulp, using materials that not only protect the pulp tissue but induce hard tissue  
36 formation for repair and maintenance [1-5]. After direct pulp capping and pulpotomy, resident dental  
37 pulp cells (DPCs) are influenced by the choice of dental material used for treatment. This knowledge  
38 led to the design and introduction of new, bioactive agents in pulp capping materials that can  
39 accelerate and improve the repair process.

40 Previous studies have shown that enamel matrix derivative (EMD)—an extract of porcine fetal  
41 tooth material—can enhance the proliferation and mineralization of dental pulp cells (DPCs) [6, 7].  
42 EMD has been used for periodontal tissue regenerative surgery, and evidence suggests that EMD can  
43 induced hard tissue formation, such as new cementum and bone tissue [8, 9]. We previously showed  
44 that subcutaneous injections of EMD on the backs of rats can induce cartilage-like tissue formation  
45 and eosinophilic round bodies (ERBs) [10]. We further analyzed these ERBs using MALDI-TOF, and  
46 found fragments of the exon 5 of amelogenin, a protein involved in the production of enamel.

47 We synthesized a 7-amino acid (WYQNMIR) peptide based on these fragments found in vivo,  
 48 and we tested whether the SP would behave similarly to EMD and induce cementum and bone-like  
 49 tissue. We found that the SP could induce hard tissue formation in periodontal artificial defects in  
 50 rats [11, 12]. Moreover, we found that the SP could promote proliferation of human periodontal  
 51 ligament (PDL) fibroblasts [13], and enhance osteogenic differentiation of human mesenchymal stem  
 52 cells (MSCs) and PDL stem cells [14-16].


53 Previous studies have shown that EMD induces the production of an antibody [17], and it is  
 54 generally recognized that peptides longer than 10 residues or those over 5 kDa can function as an  
 55 antigen [18, 19]. Given that our synthetic peptide was only 7 amino acids (1,118 Da), it is unlikely to  
 56 be at risk of producing an antibody.

57 Mitogen-activated protein kinases (MAPKs) are essential regulators of cell proliferation and  
 58 differentiation in PDL cells and DPCs [20-22]; however, the mechanism of action of the SP in  
 59 periodontal regeneration remains unclear. It is also unclear whether the SP would influence dental  
 60 pulp stem cells (DPSCs), which have a critical role of dental pulp homeostasis. Therefore, the aim of  
 61 this study was to investigate the effect of the SP on the proliferation, differentiation, and  
 62 mineralization of human DPSCs, and to test whether the SP acts through the MAPK signaling  
 63 pathway.

## 64 2. Results

### 65 2.1. Cell proliferation


66 We first tested varying concentrations of the SP on DPC cells to determine an effective  
 67 concentration. We found that the SP significantly promoted DPC proliferation at 1, 3 and 7 days (Fig.  
 68 1, \* $p < 0.05$ ), with a concentration of 100 ng/ml generating the highest change in cell proliferation  
 69 among the tested concentrations. From these results, we chose 100 ng/mL SP as the optimal  
 70 concentration for subsequent experiments.



71 **Figure 1.** Effect of the synthetic peptide (SP) on cell proliferation on dental pulp cells (DPCs).  
 72 DPCs were treated with 0, 10, 100, or 1000 ng/ml SP diluted in 100  $\mu$ l of culture medium. Cell  
 73 proliferation was measured on days 1, 3, and 7. Significant differences (\* $p > 0.05$ ) were determined as  
 74 compared with the control (no SP, 0 ng/mL).  
 75  
 76  
 77  
 78

## 79 2.2. Cell migration

80 Migration was tested using a modified Boyden chamber assay. As shown Fig. 1B, cell migration  
 81 in the experimental group (0% FBS with SP 100 ng/mL) and in the 10% FBS group (positive control)  
 82 was greater than that in the negative control group (0% FBS without SP).




83 **Figure 2.** Effects of the SP on cell migration (\* $p > 0.05$ ).

84  
85

## 86 2.3. Wound healing

87 The effect of the SP on wound repair was evaluated using a wound healing assay kit. As shown  
 88 in Fig. 3A and 3B, wound healing was significantly faster in the cultures treated with the SP as  
 89 compared with the control group.




90 **Figure 3.** Effects of the SP on wound healing. Wound healing was measured after 0 and 12 h  
 91 (Scale bar, 200  $\mu\text{m}$ ). (A) The change in the wound area is presented as the ratio of the final to initial  
 92 wound sizes. (B) Quantitative data showing the wounded area. \* $p > 0.05$ .

93  
94  
95  
96  
97  
98  
99

## 100 2.4. ALP activity and OCN production


101 ALP activity and OCN production in the SP-treated group were significantly increased  
 102 compared with cells treated with osteogenic media only (Osteo group; Fig. 4A, B;  $p < 0.05$ ).  
 103



104  
 105 **Figure 4.** Effect of the synthetic peptide (SP) on dental pulp cell (DPC) osteogenic differentiation  
 106 and mineralization. Confluent DPCs were treated with osteogenic medium (Osteo) with or without  
 107 100 ng/ml SP for 7 and 14 days ( $*P > 0.05$ ), and tested for changes in alkaline phosphatase (ALP)  
 108 activity and osteocalcin (OCN) production. (4A and B)  
 109

## 110 2.5. Quantitative Real-Time PCR Analysis of Osteogenesis-Related Gene Expression


111 The mRNA expression levels of Col1A1, Runx2, and ON were all significantly enhanced in the  
 112 SP group as compared to the Osteo group at both time points (Fig. 5A, B, C) ( $*p < 0.05$ ).  
 113  
 114



115 **Figure 5.** Effects of the SP on mRNA expression of (A) collagen 1-alpha 1 (COL1A1), (B) Runx2,  
 116 and (C) osteonectin (ON). The mRNA levels were analyzed by quantitative RT-PCR ( $*p > 0.05$ ).  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125

## 126 2.6. Alizarin red staining


127 Calcified nodules stained with Alizarin Red were larger in the SP-treated group than those in  
 128 the Osteo group (Fig. 6).  
 129



130  
 131 **Figure 6.** Effect of the SP on the mineralized nodule formation, as measured with Alizarin Red  
 132 staining. Scale bar = 100  $\mu$ m.  
 133

134  
 135 2.7. Calcium and phosphate deposition in the extracellular matrix


136 Calcium deposition in the SP-treated group was significantly promoted at both days 7 and 14 as  
 137 compared with the Osteo group (Fig. 7A; \* $p < 0.05$ ), as was the Ca/P ratio at day 7 (Fig. 7B; \* $p < 0.05$ ).  
 138



139  
 140  
 141 **Figure 7.** (A) calcium deposition, and (B) phosphate deposition (ratio of Ca/P) in the extracellular  
 142 matrix. (\* $p > 0.05$ )  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151

## 152 2.8. The activation of the MAPK signaling pathway

153 The SP activated the protein expression levels of phospho-ERK, phospho-JNK, and phospho-p38,  
 154 with the greatest change evident at SP (Fig. 8A). The ratio of phosphor-ERK 1/2 intensity. The  
 155 expression levels of (phosphor-ERK 1/2) (ERK 1/2) were increased at 60 min (Fig. 8B). The ratio of  
 156 phosphor-JNK intensity. The expression levels of (phosphor-JNK) (JNK) were increased at 30 min  
 157 (Fig. 8C). (D) The ratio of phosphor-p-38 intensity. The expression levels of (phosphor-p-38) (p-38)  
 158 were increased at both 30 and 60 min (Fig. 8D).



159 **Figure 8.** Effect of the synthetic peptide (SP) on the activation of MAPK signaling pathway  
 160 components. Dental pulp cells were cultured in medium with or without 100 ng/ml SP for 0, 30, or  
 161 60 min. Protein expression was evaluated by immunoblotting analysis. (A) Protein expression of ERK  
 162 1/2, JNK, p-38, phosphor-ERK 1/2, phosphor-JNK, and phosphor-p-38. (B) The ratio of phosphor-ERK  
 163 1/2 intensity. The expression levels of (phosphor-ERK 1/2) (ERK 1/2) were increased at 60 min. (C)  
 164 The ratio of phosphor-JNK intensity. The expression levels of (phosphor-JNK) (JNK) were increased  
 165 at 30 min. (D) The ratio of phosphor-p-38 intensity. The expression levels of (phosphor-p-38) (p-38)  
 166 were increased at both 30 and 60 min.  
 167

## 168 3. Discussion

169 EMD and other enamel matrix proteins promote the proliferation of dental tissue cells, such as  
 170 PDL cells [16,22] and dental pulp cells. In our previous study, we showed that the SP derived from  
 171 the response of cells to EMD can also promote PDL cell [24] and BMSC [14] proliferation. However,  
 172 the effects of the SP on DPCs had yet to be tested. In the present study, we show that the SP promotes  
 173 DPC proliferation at 100 ng/mL, similar to the concentration found to be optimal for PDL cells [24]  
 174 and PDL stem cells. [16] Therefore, we further investigated the effects of 100 ng/mL SP on osteogenic  
 175 differentiation and mineralization using this concentration.

176 Cell migration is necessary for homeostatic tissue maintenance and the regeneration of injured  
 177 tissues. The promotion of wound healing in dental pulp tissue is a key determinant of the success of  
 178 endodontic therapy. We found that the SP promoted the migration of DPCs using a transwell

179 chamber assay and a wound healing assay. Therefore, we conclude that the SP can promote the  
180 migration of cells that will contribute to dental pulp tissue repair and regeneration.

181 ALP and OCN are considered to be markers of osteogenesis phenotype. [25, 26] In the present  
182 study, we found that the SP promoted ALP activity and OCN production, which is reminiscent of  
183 the effect of EMD in hard tissues and the effect of SP in human MSCs [14] and PDLSCs. [16] Therefore,  
184 the SP similarly can induce the differentiation of DPCs. Runx2, ON, and COL1A1 are essential factors  
185 required during the early stages of osteogenic differentiation. [27-29] COL1A1 in particular has an  
186 important role in the formation of new hard tissue. [30] Previous work has shown that EMD can  
187 promoted the expression of all three genes in human osteoblasts and human DPCs. [31] Similarly,  
188 the SP can promote the expression of COL1A1, Runx2 and ON in human PDLSCs, [16] and promotes  
189 the expression of type I collagen after injection into artificial periodontal defect sites. [12] In the  
190 present study, we found that the SP promoted the mRNA expression of Runx2, ON, and COL1A1 in  
191 DPCs, suggesting that the SP enhances osteogenic differentiation in DPCs during the early stages of  
192 differentiation.

193 Previous work has shown that EMD promotes the mineralization of DPCs, [31] and that the SP  
194 can also promote PDLSCs mineralization. [16] Here, we qualitatively and quantitatively determined  
195 changes in mineralization in response to treatment with the SP. We found that the SP induced more  
196 mineralized nodule formation and calcium deposition on days 7 and 14 as compared with cultures  
197 without the SP. Furthermore, the SP promoted the Ca/P ratio at 7 days of culture as compared with  
198 control conditions. The theoretical Ca/P ratio of 1.67 is indicative of stoichiometrically pure  
199 hydroxyapatite. [32] Therefore, our findings suggest that the SP promotes the formation of high-  
200 quality mineralized nodules in DPCs at the early stages of mineralization. Our results suggest that  
201 the SP can be used to promote the formation of numerous, high-quality, mineralized nodules in DPCs  
202 for earlier protection to the dental pulp tissue.

203 As shown in Fig. 8, the SP induced the activation of MAPK components in human DPCs. It has  
204 been suggested that EMD and the other amelogenin peptides can regulate cellular functions through  
205 MAPK signaling. [21, 22] Therefore, our findings suggest that the SP might also regulate cellular  
206 function through MAPK signaling as well as EMD. However, the detailed molecular mechanism of  
207 action of the SP remains unclear and requires further clarification in future studies.

## 208 4. Materials and Methods

### 209 4.1. Cell culture

210 Human DPCs were purchased from Lonza (Tokyo, Japan). According to manufactures protocol,  
211 the DPCs have the undifferentiated ability. DPCs were incubated in normal culture medium  
212 containing DMEM supplemented with 10% fetal bovine serum (Gibco BRL, Life Technologies; Grand  
213 Island, NY, USA), 500 U/mL penicillin and 500 µg/mL streptomycin (Nacalai Tesque; Kyoto, Japan).  
214 DPCs were seeded into T75 culture dishes (Falcon BD; Franklin Lakes, NJ, USA) and incubated at  
215 37°C in 5% CO<sub>2</sub>. DPSCs at passage 3 to 4 were used for experimentation. For differentiation assays,  
216 cells were cultured in medium containing 50 µM L-ascorbic acid 2-phosphate (Nacalai), 10 mM β-  
217 glycerophosphate (Wako Pure Chemical Industries Ltd.; Tokyo, Japan), and 10 nM dexamethasone  
218 (Wako Pure Chemical Industries Ltd.), hereafter referred to as osteogenic medium.

### 219 4.2. Cell proliferation assay

220 DPCs were seeded in 96-well plates at  $2 \times 10^3$  cells/well in normal culture medium. After 24 h, the  
221 medium was replaced with normal culture medium containing varying concentrations of the SP (10,  
222 100, or 1000 ng/mL and without SP), and DPCs were cultured for 1, 3 or 7 days. Cell proliferation was  
223 determined by measuring the amount of formazan using the Cell Count Reagent SF (Nacalai). The  
224 absorbance was measured at 450 nm, and data were analyzed with the SoftMax Pro software  
225 (Molecular Devices; Sunnyvale, CA, USA).

226  
227

#### 228 4.3. Transwell migration assay

229 A modified Boyden chamber assay was performed using 24-well microchemotaxis chambers  
230 (Fluoroblock insert system; Falcon). DPCs were cultured with 4  $\mu$ M Calcein AM solution (Dojindo  
231 Laboratory, Kumamoto, Japan) for 30 min at 37°C. Cells were then trypsinized, washed in medium,  
232 and resuspended in serum-free medium to a final concentration of  $2.5 \times 10^4$  cells/500  $\mu$ L. The cell  
233 suspension was then added to the upper chamber of a cell culture insert, and 750  $\mu$ L of medium  
234 containing the SP (0, 100 ng/mL) or medium containing 10% FBS as a positive control was added to  
235 the lower chamber. The upper and lower wells were separated by a 3.0- $\mu$ m pore size HTS  
236 FluoroBLock Insert (Falcon). Cell migration was observed for 1, 5, and 8 h. The number of DPCs that  
237 passed through the filter to the lower chamber was evaluated using a fluorescence plate reader at 485  
238 nm/530 nm excitation/emission.

#### 240 4.4. Wound healing assay

241 In vitro wound healing assays were performed using a wound repair assay kit (Ibidi GmbH, Am  
242 Klopterspitz 19, Martinsried, Germany). DPCs were seeded at  $3.5 \times 10^4$  cells/70  $\mu$ L into a cell culture  
243 insert. After confluence, the culture insert was lifted to replace the media with serum-free medium  
244 containing the SP (0, 100 ng/mL). The culture insert was then replaced into the media, and a wound  
245 approximately 500  $\mu$ m wide was created. DPCs were cultured for a further 12 h, then fixed with 70%  
246 ethanol (Nacalai) for 10 min, and stained with 0.1% crystal violet (Merck Millipore, Darmstadt,  
247 Germany) for 5 min at room temperature. Pictures of each wound were taken at 0 h and 12 h with a  
248 BZ-II all-in-one fluorescence microscope (Keyence Corporation; Osaka, Japan). The images were used  
249 to measure the denuded area by Image J. Data are presented as the percentage of the healed wound  
250 area at 12 h as compared with the initial wound at 0 h.

#### 252 4.5. ALP activity and measurement of OCN

253 DPCs were cultured with osteogenic medium for 7 or 14 days, and then washed with PBS and  
254 lysed with 300  $\mu$ L of 0.2% Triton X-100 (Sigma-Aldrich). ALP activity was measured using a 1-step  
255 pNPP substrate (Pierce Biotechnology Inc.; Rockford, IL, USA). ALP activity was normalized to the  
256 amount of DNA in the cell lysate. The DNA content was measured using the PicoGreen dsDNA  
257 Assay kit (Invitrogen; Paisley, UK). Data were analyzed with the SoftMax Pro software. The cultured  
258 supernatant (at 7 and 14 days) was collected to quantify OCN levels using an ELISA kit (Takara Inc.;  
259 Shiga, Japan).

#### 261 4.6. Quantitative Real-Time PCR

262 DPCs were cultured with osteogenic medium for 7 or 14 days. Total cellular RNA was extracted  
263 using a kit, and 10  $\mu$ L of RNA from each sample were reverse transcribed into cDNA using a kit  
264 (PrimeScript Reagent kit; Takara). Gene expression was evaluated using a real-time PCR assay  
265 (TaqMan gene expression assay; Applied Biosystems, Thermo Fisher Scientific; Waltham, MA, USA).  
266 The mRNA expression levels of collagen type 1 alpha 1 (Col1A1; Hs00164004\_m1) osteonectin (ON;  
267 Hs00213568\_m1), and Runt-related transcription factor 2 (Runx2; Hs01047973\_m1) were determined  
268 by quantitative real-time PCR according to standard protocols.

#### 270 4.7. Extracellular matrix mineralization

271 DPCs were cultured with osteogenic medium for 7 or 14 days, using normal culture medium as  
272 a negative control. For measurements of calcium production, DPCs were dissolved with 10% formic  
273 acid, and calcium deposition (Ca) in the extracellular matrix was measured using a Calcium E test kit  
274 (Wako). The amount of phosphate was quantified using a P test kit (Bio Assay Systems; Hayward,  
275 CA, USA).

276 For qualitative histology, other cultures of DPCs at days 7 and 14 were washed with PBS and  
277 fixed with 70% ethanol (Nacalai) for 10 min. Cells were then stained with 1% Alizarin Red S for 5 min  
278 at room temperature. Calcified nodules were imaged with an BZ-II all-in-one fluorescence  
279 microscope (Keyence).

280

281 4.8. *Western blot analyses*

282 Adherent DPCs were cultured for 0, 30, and 60 min in the presence of the SP. Total protein was  
283 extracted using a buffer solution (RIPA buffer, Thermo Fisher Scientific, Rockford, IL) supplemented  
284 with a protease inhibitor cocktail. Total protein concentrations were measured using a BCA Protein  
285 Assay kit (Pierce Biotechnology). Protein samples were electrophoresed on 12.5% SDS gels, and  
286 transferred onto polyvinylidene difluoride membranes. The membranes were treated with blocking  
287 solution (Blocking One, Nacalai) and then incubated for 1 h at room temperature with primary  
288 antibodies (ERK, phospho-ERK, JNK, phospho-JNK, p38, and phospho-p38). Membranes were then  
289 washed and incubated with secondary antibodies for 1 h at room temperature. Immunoreactive  
290 bands were visualized using a chemiluminescence kit (Nacalai) and signals were analyzed with the  
291 ChemiDoc MP System (BioRad).

292

293 4.9. *Statistical Analysis*

294 A one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test was used to  
295 determine significance. P values < 0.05 were considered significant.

296 5. **Conclusions**

297 We found that the amelogenin exon5 encoded peptide derived from EMD can promote the  
298 proliferation, migration, differentiation and mineralization of DPCs at first time. Our findings  
299 suggest that the SP might be a useful agent for dental pulp repair.

300

301 **Acknowledgments:** This study was supported in part by a Grant-in-Aid for Scientific Research (C) (No.  
302 16K11617, 16K11847, 16K20476, 16K20551, and 17K11818). We would like to thank the staff of the Department  
303 Oral Pathology and Periodontology. The authors deny any conflicts of interest related to this study support of  
304 your research work. Clearly state if you received funds for covering the costs to publish in open access.

305 **Author Contributions:** Hirohito Kato and Yoichiro Taguchi conceived and designed the experiments; Hirohito  
306 Kato, Masahiro Noguchi, Kazutaka Imai, Ruan Yaru, and Saitatsu Takahashi performed the experiments;  
307 Hirohito Kato, Yoichiro Taguchi, Daisuke Kimura and Makoto Umeda analyzed the data; Kazuya Tominaga,  
308 Reiko Taguchi, Muneyasu Shida, Hiroshi Maeda and Akio Tanaka contributed reagents/materials/analysis tools;  
309 Hirohito Kato and Yoichiro Taguchi wrote the paper.

310 **Conflicts of Interest:** The authors declare no conflict of interest.

311 **Abbreviations**

EMD	enamel matrix derivative
DPCs	dental pulp cells
SP	synthetic oligo peptide
MAPK	mitogen-activated protein kinases
ERBs	eosinophilic round bodies
PDL	periodontal ligament
MSCs	mesenchymal stem cells
ALP	alkaline phosphatase
OCN	osteocalcin
Osteo	osteogenic medium
Col1A1	collagen 1-alpha-1
ON	osteonectin

312 **References**

- 313 1. Bergenholtz, G; Mjör, IA; Cotton, WR; Hanks, CT; Kim, S; Torneck, CD; Trowbridge, HO. The biology of  
314 dentin and pulp. Consensus report. *J Dent Res.* **1985**, *64*, 631–633.
- 315 2. Couve, E. Ultrastructural changes during the life cycle of human odontoblasts. *Arch Oral Biol.* **1986**, *31*, 643–  
316 651.

- 317 3. Bergenholtz, G. Advances since the paper by Zander and Glass (1949) on the pursuit of healing methods  
318 for pulpal exposures: historical perspectives. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* **2005**, *100*,  
319 S102–S108.
- 320 4. Pashley, DH. Dynamics of the pulpo-dentin complex. *Crit Rev Oral Biol Med.* **1996**, *7*, 104–133.
- 321 5. Zander, HA; Glass, RL. The healing of phenolized pulp exposures. *Oral Surg Oral Med Oral Pathol.* **1949**, *2*,  
322 803–810.
- 323 6. Nakamura, Y; Hammarström, L; Matsumoto, K; Lyngstadaas, SP. The induction of reparative  
324 dentine by enamel proteins. *Int Endod J.* **2002**, *35*, 407–417.
- 325 7. Nakamura, Y; Slaby, I; Matsumoto, K; Ritchie, HH; Lyngstadaas, SP. Immunohistochemical  
326 characterization of rapid dentin formation induced by enamel matrix derivative. *Calcif Tissue Int.* **2004**, *75*,  
327 243–252.
- 328 8. Hammarström, L. Enamel matrix, cementum development and regeneration. *J Clin Periodontol.* **1997**, *24*,  
329 658–668.
- 330 9. Hammarström, L; Heijl, L; Gestrelus, S. Periodontal regeneration in a buccal dehiscence model in monkeys  
331 after application of enamel matrix proteins. *J Clin Periodontol.* **1997**, *24*, 669–677.
- 332 10. Kim, NH; Tominaga, K; Tanaka, A. Analysis of eosinophilic round bodies formed after injection of enamel  
333 matrix derivative into the backs of rats. *J Periodontol.* **2005**, *76*, 1934–1941.
- 334 11. Yuan, K; Hsu, CW; Tsai, WH. The induction and possible subsequent effect of human antibodies against  
335 porcine enamel matrix derivative. *J Periodontol.* **2006**, *77*, 1355–1361.
- 336 12. Shinnick, TM; Sutcliffe, JG; Green, N; Lerner, RA. Synthetic peptide immunogens as vaccines. *Ann Rev*  
337 *Microbiol.* **1983**, *37*, 425–446.
- 338 13. Lerner, RA. Tapping the immunological repertoire to produce antibodies of predetermined specificity.  
339 *Nature.* **1982**, *299*, 593–596.
- 340 14. Hida, T; Tominaga, K; Tanaka, A. Tissue Reaction to synthetic oligopeptide derived from enamel matrix  
341 derivative in rats. *Oral Sci Int.* **2010**, *7*, 26–33.
- 342 15. Noguchi, M; Tominaga, K; Tanaka, A; Ueda, M. Hard tissue formation induced by synthetic oligopeptide  
343 derived from an enamel matrix derivative. *Oral Med Pathol.* **2012**, *16*, 75–80.
- 344 16. Kawanaka, A; Tominaga, K; Tanaka, A. Effect of peptide derived from Emdogain on human periodontal  
345 ligament fibroblasts. *J Osaka Dent Univ.* **2009**, *43*, 111–117.
- 346 17. Katayama, N; Kato, H; Taguchi, Y; Tanaka, A; Umeda, M. The effects of synthetic oligopeptide derived  
347 from enamel matrix derivative on cell proliferation and osteoblastic differentiation of human mesenchymal  
348 stem cells. *Int J Mol Sci.* **2014**, *15*, 14026–14043.
- 349 18. Yasui, N; Taguchi, Y; Tanaka, A; Ueda, M; Umeda M. Biological effects of emdogain-derived oligopeptides  
350 on rat bone marrow cells in vitro. *J Oral Tissue Eng.* **2012**, *9*, 126–135.
- 351 19. Kato, H; Katayama, N; Taguchi, Y; Tominaga, K; Umeda, M; Tanaka, A. A synthetic oligopeptide derived  
352 from enamel matrix derivative promotes the differentiation of human periodontal ligament stem cells into  
353 osteoblast-like cells with increased mineralization. *J Periodontol.* **2013**, *84*, 1476–1483.
- 354 20. Junttila, MR; Li, SP; Westermarck, J. Phosphatase-mediated crosstalk between MAPK signaling pathways  
355 in the regulation of cell survival. *FASEB J.* **2008**, *22*, 954–965.
- 356 21. Matsuda, N; Horikawa, M; Watanabe, M; Kitagawa, S; Kudo, Y; Takata, T. Possible involvement of  
357 extracellular signal-regulated kinases 1/2 in mitogenic response of periodontal ligament cells to enamel  
358 matrix derivative. *Eur J Oral Sci.* **2002**, *110*, 439–444.
- 359 22. Wang, Y; Zhao, Y; Ge, L. Effects of the enamel matrix derivative on the proliferation and odontogenic  
360 differentiation of human dental pulp cells. *J Dent.* **2014**, *42*, 53–59.
- 361 23. Guida, L; Annunziata, M; Carinci, F; Di, Feo A; Passaro, I; Oliva, A. In vitro biologic response of human  
362 bone marrow stromal cells to enamel matrix derivative. *J Periodontol.* **2007**, *78*, 2190–2196.
- 363 24. Taguchi, Y; Yasui, N; Takahashi, S; Tominaga, K; Kato, H; Komasa, S; Shida, M; Hayashi, H; Tanaka, A;  
364 Umeda, M. Hard tissue formation by human periodontal ligament fibroblast Cells treated with an  
365 emdogain-derived oligopeptide in vitro. *J Hard Tissue Biol.* **2012**, *21*, 375–384.
- 366 25. Weinreb, M; Shinar, D; Rodan, GA. Different pattern of alkaline phosphatase, osteopontin, and osteocalcin  
367 expression in developing rat bone visualized by in situ hybridization. *J Bone Miner Res.* **1990**, *5*, 831–842.
- 368 26. Ikeda, T; Nomura, S; Yamaguchi, A; Suda, T; Yoshiki, S. In situ hybridization of bone matrix proteins in  
369 undecalcified adult rat bone sections. *J Histochem Cytochem.* **1992**, *40*, 1079–1088.

- 370 27. Ishigaki, R; Takagi, M; Igarashi, M; Ito, K. Gene expression and immunohistochemical localization of  
371 osteonectin in association with early bone formation in the developing mandible. *Histochem J.* **2002**, *34*, 57–  
372 66.
- 373 28. Aubin, JE; Liu, F; Malaval, L; Gupta, AK. Osteoblast and chondroblast differentiation. *Bone.* **1995**, *17*(Suppl.  
374 2), 77S–83S.
- 375 29. Ohyama, M; Suzuki, N; Yamaguchi, Y; Maeno, M; Otsuka, K; Ito, K. Effect of enamel matrix derivative on  
376 the differentiation of C2C12 cells. *J Periodontol.* **2002**, *73*, 543–550.
- 377 30. Wiesmann, HP; Meyer, U; Plate, U; Höhling, HJ. Aspects of collagen mineralization in hard tissue  
378 formation. *Int Rev Cytol.* **2005**, *242*, 121–156.
- 379 31. Karanxha, L; Park, SJ; Son, WJ; Nor, JE; Min, KS. Combined effects of simvastatin and enamel matrix  
380 derivative on odontoblastic differentiation of human dental pulp cells. *J Endod.* **2013**, *39*, 76–82.
- 381 32. Wang, W; Yi, X; Ren, Y; Xie, Q. Effects of adenosine triphosphate on proliferation and odontoblastic  
382 differentiation of human dental pulp cells. *J Endod.* **2016**, *42*, 1483–1489.